ChemoCentryx (NASDAQ:CCXI) Upgraded at BidaskClub

BidaskClub upgraded shares of ChemoCentryx (NASDAQ:CCXI) from a sell rating to a hold rating in a research note published on Wednesday, March 14th.

Separately, JPMorgan Chase reaffirmed an overweight rating and set a $16.00 target price (up previously from $13.00) on shares of ChemoCentryx in a research note on Tuesday, March 13th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of $15.00.

How to Become a New Pot Stock Millionaire

ChemoCentryx stock traded down $0.33 during midday trading on Wednesday, reaching $12.33. 148,688 shares of the company’s stock were exchanged, compared to its average volume of 303,621. ChemoCentryx has a 52 week low of $5.42 and a 52 week high of $15.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.46 and a current ratio of 5.46. The stock has a market capitalization of $626.18, a P/E ratio of 34.25 and a beta of 1.58.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Friday, March 9th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $1.02. The company had revenue of $56.30 million for the quarter, compared to analyst estimates of $9.03 million. research analysts forecast that ChemoCentryx will post -1.18 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC raised its holdings in shares of ChemoCentryx by 16.9% during the fourth quarter. Millennium Management LLC now owns 255,831 shares of the biopharmaceutical company’s stock valued at $1,522,000 after purchasing an additional 37,069 shares during the period. TIAA CREF Investment Management LLC raised its holdings in shares of ChemoCentryx by 10.1% in the 4th quarter. TIAA CREF Investment Management LLC now owns 121,132 shares of the biopharmaceutical company’s stock worth $721,000 after acquiring an additional 11,124 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of ChemoCentryx by 21.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 267,066 shares of the biopharmaceutical company’s stock worth $1,589,000 after acquiring an additional 46,626 shares during the last quarter. Landscape Capital Management L.L.C. raised its holdings in shares of ChemoCentryx by 35.4% in the 4th quarter. Landscape Capital Management L.L.C. now owns 33,764 shares of the biopharmaceutical company’s stock worth $201,000 after acquiring an additional 8,825 shares during the last quarter. Finally, Unterberg Capital LLC acquired a new stake in shares of ChemoCentryx in the 4th quarter worth about $595,000. Hedge funds and other institutional investors own 48.39% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ChemoCentryx (NASDAQ:CCXI) Upgraded at BidaskClub” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/chemocentryx-ccxi-upgraded-to-hold-at-bidaskclub.html.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply